<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The present study investigated the neuroprotective potential of two novel <z:chebi fb="0" ids="51349">polyamine</z:chebi> analogues, BU43b and BU36b, when administered 30 min prior to <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Neuroprotection in a permanent and a transient focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> mouse model (induced by intraluminal middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO)) was investigated using a range of histological and behavioural assessments </plain></SENT>
<SENT sid="2" pm="."><plain>In the permanent <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> model, BU43b reduced <z:hpo ids='HP_0000969'>oedema</z:hpo> and showed a trend towards reduction in %HLV (percentage hemisphere lesion volume) when administered at a dose of 30 mg/kg i.p </plain></SENT>
<SENT sid="3" pm="."><plain>Following <z:e sem="disease" ids="C0022118" disease_type="Disease or Syndrome" abbrv="">transient ischaemia</z:e>, treatment with BU43b decreased the %HLV and reduced <z:hpo ids='HP_0000969'>oedema</z:hpo> when administered at 30 mg/kg </plain></SENT>
<SENT sid="4" pm="."><plain>BU43b also improved the locomotor activity (LMA) in MCAO mice at both 20 mg/kg and 30 mg/kg doses </plain></SENT>
<SENT sid="5" pm="."><plain>BU36b was less effective than BU43b in both the permanent and the transient models, with its most pronounced effect being a trend towards reduction in <z:hpo ids='HP_0000969'>oedema</z:hpo> in both models </plain></SENT>
<SENT sid="6" pm="."><plain>These results demonstrate that BU43b administered 30 min before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> provided a good level of neuroprotection in the two models of <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> used and may have potential as a neuroprotective treatment for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>